<DOC>
	<DOCNO>NCT00150059</DOCNO>
	<brief_summary>To evaluate efficacy safety pimecrolimus cream 1 % registered indication ( treatment patient &gt; 3 month age mild moderate atopic dermatitis ) This study enrol patient United States .</brief_summary>
	<brief_title>Efficacy Safety Pimecrolimus Cream 1 % Patients ≥ 3 Months Age With Mild Moderate Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>The patient population must consist male female outpatient , age ≥3 month old mild moderate atopic dermatitis ( IGA ≥ 1 ) . Exclusion criterion pregnancy , active viral infection site ( ) treatment , present systemic malignancy active lymphoproliferative diseases/disorders , receive phototherapy immunosuppressive therapy , use tacrolimus ointment know allergy hypersensitivity .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>atopic dermatitis , eczema , mild moderate , child , IGA</keyword>
</DOC>